28 November 2020 - Late treatment study
COVID-19 in hospitalized patients in Spain: a cohort study in Madrid
et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106249 (Peer Reviewed)
Retrospective 1255 patients in Spain showing lower mortality with HCQ. Subject to confounding by indication.
|
risk of death, 22.8% lower, RR 0.77, p = 0.26, treatment 251 of 1,148 (21.9%), control 17 of 60 (28.3%), NNT 15.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Rodriguez-Gonzalez et al., 11/28/2020, retrospective, Spain, Europe, peer-reviewed, 20 authors, average treatment delay 6.0 days.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.